Provided herein are compounds of Formula (I), and pharmaceutically acceptable salts, N-oxides, or solvates thereof,

##STR00001##

Also provided herein are pharmaceutical compositions comprising compounds of Formula (I) and methods of using compound of Formula (I).

Provided are m-diamide compounds and a preparation method therefor and the use thereof. The m-diamide compounds have a structure represented by formula I. The m-diamide compounds of the present invention can have a high insecticidal activity at a low dose and take effect rapidly, can exert the insecticidal activity one day after application, can achieve a high insecticidal activity within three days, and have a good fast-acting property; moreover, due to the good effect at a low dose, the m-diamide compounds can reduce the damage to plants and human beings caused by excessive drug concentrations, enable less drug residue to be generated during application which is more conducive to environmental protection, and have broad application prospects.

The disclosure features novel lipids and compositions involving the same. Nanoparticle compositions include a novel lipid as well as additional lipids such as phospholipids, structural lipids, and PEG lipids. Nanoparticle compositions further including therapeutic and/or prophylactics such as RNA are useful in the delivery of therapeutic and/or prophylactics to mammalian cells or organs to, for example, regulate polypeptide, protein, or gene expression.

The disclosures herein relate to novel compounds of formula (1): (1) and salts thereof, wherein A, X, R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.10 and R.sup.11 are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of disorders associated with EP.sub.4 receptors.

##STR00001##

The disclosure features novel lipids and compositions involving the same. Lipid nanoparticles (e.g., empty LNPs or loaded LNPs) include a novel lipid as well as additional lipids such as phospholipids, structural lipids, and PEG lipids. Lipid nanoparticles (e.g., empty LNPs or loaded LNPs) further including therapeutic and/or prophylactics such as RNA are useful in the delivery of therapeutic and/or prophylactics to mammalian cells or organs to, for example, regulate polypeptide, protein, or gene expression.

This present disclosure relates to protein kinase C (PKC) modulating compounds, methods of treating a subject with cancer using the compounds, and combination treatments with a second therapeutic agent.

Described herein are compounds, or pharmaceutically acceptable salts thereof, of the following formula:

##STR00001##

The compounds are useful for treating inflammatory and autoimmune diseases.

The present disclosure relates to a sulfo-substituted biaryl derivative compound or a salt thereof, a preparation method and use thereof, in particular to the compound of formula (I) wherein R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.5′, R.sub.6, R.sub.7 and X as defined in the specification or its stereoisomers, tautomers, stable isotopic derivatives, pharmaceutically acceptable salts or solvates, a method for their preparation, a pharmaceutical composition comprising the same, and use of the compounds in the manufacture of a medicament for the treatment or prevention of a disease associated with RORγt.

##STR00001##

The present document describes compounds, or pharmaceutically acceptable salt thereof, of a core formula (I) where R.sub.1 features an amine group, particularly useful in the formulation of lipid particles including nucleic acid therapeutic agents, or proteins, or both, and for delivery of nucleic acid and protein therapeutics to cells in vivo or ex vivo, including anticancer and vaccine applications.

##STR00001##

The present disclosure relates to compounds suitable for treating, ameliorating and/or preventing neuromuscular disorders, including the reversal of drug-induced neuromuscular blockade. The compounds as defined herein can inhibit the CIC-1 ion channel.